Next Article in Journal
AMPA Receptor Antagonists Facilitate NEDD4-2-Mediated GRIA1 Ubiquitination by Regulating PP2B-ERK1/2-SGK1 Pathway in Chronic Epilepsy Rats
Next Article in Special Issue
The Revival of Surgery in Crohn’s Disease—Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis
Previous Article in Journal
Sharing the Same Perspective. Mental Disorders and Central Serous Chorioretinopathy: A Systematic Review of Evidence from 2010 to 2020
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 9
Issue 8
10.3390/biomedicines9081068
Review Report
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease

Biomedicines 2021, 9(8), 1068; https://doi.org/10.3390/biomedicines9081068
by Shinya Ashizuka 1,*, Toshihiro Kita 2, Haruhiko Inatsu 1 and Kazuo Kitamura 2
Reviewer 2: Anonymous
Biomedicines 2021, 9(8), 1068; https://doi.org/10.3390/biomedicines9081068
Submission received: 28 July 2021 / Revised: 19 August 2021 / Accepted: 20 August 2021 / Published: 23 August 2021
(This article belongs to the Special Issue Novel Therapeutic Approaches in Inflammatory Bowel Diseases 2.0)

Round 1

Reviewer 1 Report

Yours is an overall good study. The analysis of the effects of the adrenomedullin and the potential use is thorough and the scientific value is also good, especially for the refractory to steroids IBD. Although I am not sure about the adverse effects, considered as mild. Your conclusion is not confirming the use of adrenomedullin as the title suggests. The plan of the study is also good as the RCTs.

Author Response

We would like to thank you for giving us the opportunity to submit a revised version of our manuscript and the reviewers for their constructive comments that have helped to substantially improve our manuscript. We have replied to these comments in detail and revised the manuscript accordingly.

We simplified the conclusion as suggested and added statement " significant efficacy can be achieved at relatively low doses, where the side effect of hypotension caused by AM is not a clinical problem." Also checked the English language.

Reviewer 2 Report

Authors present very interesting review paper about the bioactive peptide adrenomedullin (AM). In the paper they discuss the biosynthesis, receptor characteristics, and physiopathological effects of AM. The author underline the potential effects of AM in IBD patients.

I suggest to add the short paragraph about the future perspectives of AM among IBD - what further studies are warranted to confirm the role of AM in management of IBD patients to underline the role of AM in the therapy of IBD.

Author Response

We would like to thank you for giving us the opportunity to submit a revised version of our manuscript and the reviewers for their constructive comments that have helped to substantially improve our manuscript. We have replied to these comments in detail and revised the manuscript accordingly.

We added novel section: 9. Future perspectives.... Also checked the English language.

Back to TopTop